Literature DB >> 18343669

A new take on prions: preventing Alzheimer's disease.

Nigel M Hooper1, Anthony J Turner.   

Abstract

Alzheimer's disease is a major neurodegenerative disease of the brain, the incidence of which increases dramatically in old age. Currently, no drugs are available to halt or slow the progression of this disease, which poses an ever-expanding burden on health services, families and society. The prion protein has become infamous owing to its role as the causative agent of the transmissible spongiform encephalopathies such as Creutzfeldt-Jakob disease in humans. However, our view of the prion protein as an unwanted, harmful entity has been challenged recently. New data indicate that the normal cellular form of the prion protein might have a crucial role in suppressing the production of the amyloid-beta peptide, the neurotoxic molecule involved in the pathogenesis of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343669     DOI: 10.1016/j.tibs.2008.01.004

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  10 in total

1.  Regulation of amyloid-β production by the prion protein.

Authors:  Heledd H Griffiths; Isobel J Whitehouse; Nigel M Hooper
Journal:  Prion       Date:  2012-07-01       Impact factor: 3.931

2.  Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein.

Authors:  Heledd H Griffiths; Isobel J Whitehouse; Herbert Baybutt; Debbie Brown; Katherine A B Kellett; Carolyn D Jackson; Anthony J Turner; Pedro Piccardo; Jean C Manson; Nigel M Hooper
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

3.  β-Cleavage of the prion protein in the human eye: Implications for the spread of infectious prions and human ocular disorders.

Authors:  Suman Chaudhary; Ajay Ashok; Aaron S Wise; Neil A Rana; Alexander E Kritikos; Ewald Lindner; Neena Singh
Journal:  Exp Eye Res       Date:  2021-10-07       Impact factor: 3.467

Review 4.  Prion protein and Alzheimer disease.

Authors:  Katherine A B Kellett; Nigel M Hooper
Journal:  Prion       Date:  2009-10-02       Impact factor: 3.931

5.  The polybasic N-terminal region of the prion protein controls the physical properties of both the cellular and fibrillar forms of PrP.

Authors:  Valeriy G Ostapchenko; Natallia Makarava; Regina Savtchenko; Ilia V Baskakov
Journal:  J Mol Biol       Date:  2008-09-04       Impact factor: 5.469

6.  Targeting Cdk5 activity in neuronal degeneration and regeneration.

Authors:  Jyotshnabala Kanungo; Ya-li Zheng; Niranjana D Amin; Harish C Pant
Journal:  Cell Mol Neurobiol       Date:  2009-12       Impact factor: 5.046

7.  Glypican-1 mediates both prion protein lipid raft association and disease isoform formation.

Authors:  David R Taylor; Isobel J Whitehouse; Nigel M Hooper
Journal:  PLoS Pathog       Date:  2009-11-20       Impact factor: 6.823

8.  A common BACE1 polymorphism is a risk factor for sporadic Creutzfeldt-Jakob disease.

Authors:  Olga Calero; María J Bullido; Jordi Clarimón; Ana Frank-García; Pablo Martínez-Martín; Alberto Lleó; María Jesús Rey; Isabel Sastre; Alberto Rábano; Jesús de Pedro-Cuesta; Isidro Ferrer; Miguel Calero
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

9.  Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stage.

Authors:  Isobel J Whitehouse; J Scott Miners; Elizabeth B C Glennon; Patrick G Kehoe; Seth Love; Katherine A B Kellett; Nigel M Hooper
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

10.  Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic Phenotype.

Authors:  Isobel J Whitehouse; Deborah Brown; Herbert Baybutt; Abigail B Diack; Katherine A B Kellett; Pedro Piccardo; Jean C Manson; Nigel M Hooper
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.